AbbVie Inc. (ABBV)
After hours:
| Previous close | 164.25 |
| Open | 164.96 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 800 |
| Day's range | 164.43 - 167.44 |
| 52-week range | 130.96 - 182.89 |
| Volume | |
| Avg. volume | 5,637,629 |
| Market cap | 291.555B |
| Beta (5Y monthly) | 0.56 |
| PE ratio (TTM) | 60.54 |
| EPS (TTM) | 2.72 |
| Earnings date | 26 Apr 2024 |
| Forward dividend & yield | 6.20 (3.77%) |
| Ex-dividend date | 12 Apr 2024 |
| 1y target est | 184.49 |
Fool.co.uk3 top US dividend stocks for value investors to consider in 2024
I’m searching far and wide to find the best dividend stocks that money can buy. Do the Americans have more to offer when it comes to value investing? The post 3 top US dividend stocks for value investors to consider in 2024 appeared first on The Motley Fool UK.
BenzingaSoon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease Study
On Thursday, Cerevel Therapeutics Holdings Inc. (NASDAQ:CERE) released topline results from its pivotal Phase 3 TEMPO-3 trial for tavapadon in Parkinson’s disease. The TEMPO-3 trial evaluated the efficacy, safety, and tolerability of tavapadon as an adjunctive therapy to levodopa (LD) in adults. The trial met its primary endpoint – patients treated with tavapadon adjunctive to LD experienced a clinically meaningful and statistically significant increase of 1.1 hours in total “on” time without tr
PR NewswirePhase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis
AbbVie (NYSE: ABBV) today announced positive top-line results from SELECT-GCA, a Phase 3, multicenter, randomized, double-blind, placebo-controlled study, showing upadacitinib (RINVOQ®; 15 mg, once daily) in combination with a 26-week steroid taper regimen achieved its primary endpoint of sustained remissiona from week 12 through week 52 in adults with giant cell arteritis (GCA). In this study, 46 percent of patients receiving upadacitinib 15 mg in combination with a 26-week steroid taper regime
